MSON News and Press, MISONIX Inc. From 03/04/21

Misonix (MSON) announces that it has received a Health Canada license for its neXus Ultrasonic Surgical System.This approval confirms that neXus meets the requirements of Health Canada, allowing Misonix to commercialize neXus, along with its various handpieces and disposable product...

FARMINGDALE, N.Y., March 04, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announ...

FARMINGDALE, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the upcoming Cowen 41 st ...

FARMINGDALE, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Misonix Chief Executive Officer, Stavros Vizirgianaki...

Maker of ultrasonic energy based surgical tools reported its latest quarterly results highlighted by improving financials. The company is seeing strong adoption of its 'neXus' platform in the specialized spine and neurosurgical applications. New product launches expected later thi...

Gainers: T2 Biosystems (TTOO) +30%, Zomedica (ZOM) +24%, Sientra (SIEN) +18%, Misonix (MSON) +18%, Senseonics (SENS) +17%.Losers: Pro-Dex (PDEX) -22%, Veru (VERU) -21%, Twist Bioscience TWST -20%, Spero Therapeutics SPRO -19%, C...

Misonix, Inc. (MSON) Q2 2021 Earnings Conference Call February 4, 2021 4:30 PM ET Company Participants Norberto Aja – Investor Relations Stavros Vizirgianakis – President and Chief Executive Officer Joe Dwyer – Chief Financial Officer Conference Call Participants Alex Now...

MISONIX (MSON): FQ2 GAAP EPS of -$0.07 beats by $0.22.Revenue of $18.26M (-7.4% Y/Y) beats by $1.31M.Press Release For further details see: MISONIX EPS beats by $0.22, beats on revenue

FARMINGDALE, N.Y., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported financ...

FARMINGDALE, N.Y., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2021 second quarter financi...